Treating clonorchiasis with albendazole, tribendimidine, or praziquantel in Guangxi
Official title: Albendazole, Tribendimidine, and Praziquantel for Clonorchiasis in Guangxi: A Randomized Controlled Trial Comparing Efficacy and Safety
Run by First Affiliated Hospital of Guangxi Medical University · NCT07074444 · Data updated 2026-11-12
We will test which of three medicines—albendazole, tribendimidine, or praziquantel—best clears liver fluke (Clonorchis sinensis) eggs from stool in adults with clonorchiasis and record side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 318 (estimated) |
| Sponsor | First Affiliated Hospital of Guangxi Medical University Academic / other |
| Locations | 2 sites (Nanning, Guangxi and 1 other locations) |
| Status | Recruiting |
| Started | July 22, 2025 |
| Main results expected | February 28, 2027 |
| Study ends | February 28, 2027 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT07074444 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with laboratory-confirmed Clonorchis sinensis infection who can provide informed consent and attend study visits are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have severe liver, kidney, or cardiac disease, gallstones or biliary obstruction, certain heart rhythm disorders, neuro/ocular cysticercosis, or known allergy to any study drug are unlikely to benefit and are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, open-label trial comparing three commonly used antiparasitic drugs for adults with confirmed Clonorchis sinensis infection. Participants are randomly assigned to one of the three treatment regimens and provide stool samples before treatment and at follow-up to measure egg clearance. If eggs persist after the first course, the same regimen is repeated and stool is rechecked; adverse events are recorded throughout follow-up. The trial is conducted at two hospitals in Nanning, Guangxi, with standard clinical and laboratory monitoring.
Why it matters
Potential benefit: If successful, the trial could identify the most effective and safest medicine among the three for clearing Clonorchis sinensis, helping to improve cure rates and guide local treatment choices.
How similar studies have gone: Praziquantel is an established effective treatment for clonorchiasis, tribendimidine has shown promise in smaller trials, and albendazole has been used but is less consistently studied for this infection.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults aged ≥18 years. 2. Confirmed diagnosis of Clonorchis sinensis infection based on the latest Expert Consensus on Diagnosis and Treatment of Food-Borne Parasitic Diseases (2023): detection of eggs or adult worms in stool or bile drainage fluid. 3. Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Known hypersensitivity or allergy to albendazole, praziquantel, or tribendimidine. 2. Electrocardiogram (ECG)-confirmed supraventricular tachycardia or atrial fibrillation. 3. Clinically or radiologically diagnosed neurocysticercosis (brain or spinal cord) or ocular cysticercosis (eye or orbit). 4. Presence of gallbladder stones or biliary tract obstruction as confirmed by abdominal ultrasound. 5. Individuals with severe hepatic, renal, or cardiac dysfunction, or with active peptic ulcer disease. 6. Pregnant or breastfeeding individuals, or those of reproductive potential (male or female) who are unwilling to use effective contraception during the study period and for 3 months following the last dose of study medication. 7. Anticipated loss to follow-up due to relocation, withdrawal of consent, or other factors affecting adherence to the study protocol.
Where it's running
-
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China Recruiting -
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China Recruiting
Study contacts
- Principal investigator: Hongliang Zhang — First Affiliated Hospital of Guangxi Medical University
- Study coordinator: Hongliang Zhang
- Email: 277749097@qq.com
- Phone: +86 13737143253
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.